Tagrisso's primary patents are set to expire in 2027, with some expiring as early as July 2027. [1] This timeline could allow for the introduction of generic versions of the drug.
When does Tagrisso's market exclusivity end?
Market exclusivity for Tagrisso is primarily determined by its patent protection. Key patents are expected to expire in 2027, paving the way for potential generic competition. [1]
What are the key patents for Tagrisso?
The primary patents for Tagrisso, also known by its chemical name Osimertinib, are held by AstraZeneca. These patents cover the composition of matter, methods of use, and formulations of the drug. [1]
Can generic Tagrisso be available before patent expiration?
Generally, generic drugs cannot enter the market before the expiration of relevant patents. However, legal challenges or specific patent settlements could potentially alter these timelines. [2]
Who makes Tagrisso?
Tagrisso is manufactured and marketed by AstraZeneca. [3]
What is the significance of Tagrisso patent expiration?
The expiration of Tagrisso's patents is significant because it opens the door for other pharmaceutical companies to develop and market generic versions of the drug. This could lead to increased competition and potentially lower prices for patients. [2]
How does Tagrisso compare to other EGFR inhibitors?
Tagrisso is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) specifically designed to target both sensitizing and resistance mutations in EGFR. It is often used for patients with non-small cell lung cancer (NSCLC) who have specific EGFR mutations. Other EGFR inhibitors target similar pathways but may differ in their spectrum of activity against specific mutations or their side effect profiles. [4]
What are the clinical indications for Tagrisso?
Tagrisso is approved for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC). This includes both newly diagnosed patients and those whose disease has progressed on or after prior EGFR TKI therapy. [5]
What is the regulatory status of Tagrisso?
Tagrisso has received approval from major regulatory agencies worldwide, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). [5]
Where can I find more information on drug patents like Tagrisso's?
Information regarding drug patents, including expiration dates and legal challenges for medications like Tagrisso, can be found on DrugPatentWatch.com. [1]
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/faq
[3] https://www.astrazeneca.com/
[4] https://www.cancer.gov/about-cancer/treatment/drugs/lung-cancer-tkis
[5] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-and-certifications